Skip to content
ADVERTISEMENT
Sign In
  • Sections
    • News
    • Advice
    • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Student Success
    • Technology
    • Transitions
    • The Workplace
  • Magazine
    • Current Issue
    • Special Issues
    • Podcast: College Matters from The Chronicle
  • Newsletters
  • Events
    • Virtual Events
    • Chronicle On-The-Road
    • Professional Development
  • Ask Chron
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Professional Development
    • Career Resources
    • Virtual Career Fair
  • More
  • Sections
    • News
    • Advice
    • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Student Success
    • Technology
    • Transitions
    • The Workplace
  • Magazine
    • Current Issue
    • Special Issues
    • Podcast: College Matters from The Chronicle
  • Newsletters
  • Events
    • Virtual Events
    • Chronicle On-The-Road
    • Professional Development
  • Ask Chron
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Professional Development
    • Career Resources
    • Virtual Career Fair
    Upcoming Events:
    College Advising
    Serving Higher Ed
    Chronicle Festival 2025
Sign In
Research

Why Disclosure Policies Don’t Discourage Academe’s Drug Salesmen

By Paul Basken July 3, 2017
AstraZeneca is one company, along with Allergan, Otsuka, Pfizer, and Sunovion, that has financial ties to the authors of a paper that endorses their products for treatment of depression.
AstraZeneca is one company, along with Allergan, Otsuka, Pfizer, and Sunovion, that has financial ties to the authors of a paper that endorses their products for treatment of depression. Alamy

Whatever else his critics may say of Stephen M. Stahl, the adjunct professor of psychiatry at the University of California at San Diego does not appear guilty of a failure to disclose.

Earlier this year, Mr. Stahl led a group of distinguished colleagues in writing new rationales for psychiatrists to boost their offerings of drugs to depressed patients. To that document Dr. Stahl appended an encyclopedic list of industry ties.

To continue reading for FREE, please sign in.

Sign In

Or subscribe now to read with unlimited access for as low as $10/month.

Don’t have an account? Sign up now.

A free account provides you access to a limited number of free articles each month, plus newsletters, job postings, salary data, and exclusive store discounts.

Sign Up

AstraZeneca is one company, along with Allergan, Otsuka, Pfizer, and Sunovion, that has financial ties to the authors of a paper that endorses their products for treatment of depression.
AstraZeneca is one company, along with Allergan, Otsuka, Pfizer, and Sunovion, that has financial ties to the authors of a paper that endorses their products for treatment of depression. Alamy

Whatever else his critics may say of Stephen M. Stahl, the adjunct professor of psychiatry at the University of California at San Diego does not appear guilty of a failure to disclose.

Earlier this year, Mr. Stahl led a group of distinguished colleagues in writing new rationales for psychiatrists to boost their offerings of drugs to depressed patients. To that document Dr. Stahl appended an encyclopedic list of industry ties.

The article, published in February in CNS Spectrums, encourages the diagnosis and pharmaceutical treatment of “mixed depression,” and it lists 26 different drug companies for which Dr. Stahl serves as a consultant, 24 companies that have given him research grants, six companies for which he serves as a public speaker, and one for which he serves on the board.

Health-care industry manufacturers last year reported $8.1 billion in payments to hundreds of thousands of physicians.
His 19 co-authors also are recognized leaders in their field from institutions that include Harvard University, Stanford University, the University of Pennsylvania, and the Icahn School of Medicine at Mount Sinai. According to two full pages of disclosures at the bottom of the article, most of them maintain multiple financial ties to the pharmaceutical companies whose products they endorsed in the article.

The case was highlighted last month at an academic conference by Lisa Cosgrove, a professor of counseling and school psychology at the University of Massachusetts at Boston. Ms. Cosgrove didn’t name the authors in her presentation, saying she was less interested in pursuing any particular individual and more concerned about highlighting a problem she sees as still widespread despite persistent efforts to tackle it.

Universities, in response to years of revelations and lawsuits about companies paying scientists to help promote their products through scientifically dubious research presentations, have been enacting tougher policies governing financial conflicts and disclosures. Federal agencies and Congress have done the same. And yet, as Dr. Stahl’s case suggests, it’s clearly not enough, Ms. Cosgrove said.

“It’s a poster child,” Ms. Cosgrove said after her presentation at the PharmedOut conference at Georgetown University, “for all the economies of influence that undermine patient-centered medicine.”

Dr. Stahl, through an assistant, said he was on an extended trip to Europe and could not respond to questions about the article in CNS Spectrums, where he also serves as editor in chief. He is also chairman of both the Neuroscience Education Institute, which provides doctors with continuing medical education, and the Arbor Scientia Group, which provides medical writing services and “promotional medical education.”

The summary contained in Ms. Cosgrove’s presentation was enough to prompt the University of California to investigate. “It is concerning,” Dianne Klein, a spokeswoman for the university system, said in a written response to the points Ms. Cosgrove raised. “And as such, we plan to take a deeper look at the issue to discern the facts and address any conflicts of interest arising from this individual’s association with the university.”

ADVERTISEMENT

Studies have been showing for years, however, that academic scientists with financial ties to industry tend, on average, to overstate benefits and underreport risks of the products they investigate. And federal investigators in the past have found Dr. Stahl guilty of misleading work.

Lack of ‘Systematic Review’

The Stahl team’s report is an attempt to guide doctors in interpreting the latest update to the Diagnostic and Statistical Manual of Mental Disorders, the profession’s chief diagnostic tool, published by the American Psychiatric Association. That update, issued in 2013, formally endorsed the mixed-depression concept.

The drugs that Dr. Stahl and his team recommended for its treatment include lurasidone, an antipsychotic sold under the brand name Latuda and marketed by Sunovion, one of the companies for which Dr. Stahl serves as a consultant and speaker. Other companies with both financial ties to the authors and drugs recommended by them include Allergan, AstraZeneca, Otsuka, and Pfizer.

Ms. Cosgrove said her preliminary investigative work suggests the $1,000-a-month lurasidone and other drugs touted in the Stahl article have been found no more effective than cheaper alternatives.

ADVERTISEMENT

But either way, she said, a central problem with the Stahl team’s work and many other medical-journal articles is the lack of any sign the authors conducted a “systematic review” — a formal search of the scientific literature for previous studies, aimed at ensuring that any summary recommendation includes a balanced assessment of prior discoveries.

Dr. Stahl’s report was written in the style of a formal set of prescribing guidelines for doctors, and its recommended change to those guidelines was attributed to seven patient trials. All of those trials had at least one author who is an industry employee, Ms. Cosgrove said. For five of those seven trials, every author had ties to the drug companies involved, she said. And a co-author on the Stahl team was the lead author on four of those seven trials, she said.

Congress, as part of the comprehensive health-care bill enacted in 2010 — known as the Affordable Care Act, or Obamacare — included provisions requiring drug and medical-supply companies to publicly report all financial relationships with physicians and teaching hospitals.

The disclosure provision has been a “success,” one of the measure’s lead authors, Sen. Charles E. Grassley, Republican of Iowa, said through a spokeswoman. As a result of it, he said, health-care industry manufacturers last year reported $8.1 billion in various types of payments to hundreds of thousands of physicians. Nearly $25 billion in payments have been recorded since the system began in 2013, he said.

ADVERTISEMENT

The overall value of such transparency measures — including the deterrent effect — cannot be fully known, acknowledged the spokeswoman, Jill Gerber. But disclosure lets both patients and investigators hunt for problems, and it may be especially effective against specific high-profile problems such as the overprescribing of opioids, she said.

Ms. Cosgrove expressed doubt. “Transparency is an insufficient solution to the problem of the corruption of the evidence base because it can’t guard against implicit bias, and may even be dangerous,” she said. That danger, she said, is the possibility of making the problem of bias appear solved when it has merely changed forms.

Lawsuits and Liabilities

There is the possibility of legal actions to hold various parties — including those at universities — responsible for prescription abuses that harm patients. Several states have filed lawsuits in recent weeks accusing major drug companies of fraudulently misrepresenting the risks of opioid painkillers now blamed in tens of thousands of deaths a year. The lawsuits typically have charged only the companies as the defendants, though some university scientists have been named by state prosecutors as taking part in the strategy to mislead.

Transparency is an insufficient solution to the problem of the corruption of the evidence base because it can’t guard against implicit bias, and may even be dangerous.
Universities are generally confident that their ethics policies and practices leave them protected from such legal liability, according to the Association of American Medical Colleges. Such policies, however, tend to vary in their terms and applicability. As for speakers bureaus — which typically involve presentations to doctors designed to promote drug-company products — some universities prohibit the practice while others only discourage it or require preapproval for such activities.

ADVERTISEMENT

The University of California system does not prohibit faculty from serving on corporate speakers bureaus, “but the practice is discouraged,” said Scott Lafee, a spokesman for UC-San Diego.

UC does have policies governing outside activities and earnings disclosures, but those are applicable only to faculty with appointments covering greater than 50 percent of their time. Dr. Stahl is a nonsalaried adjunct professor with exactly a 50-percent staff-physician appointment, meaning the disclosure rules do not apply to him, Mr. Lafee said.

Dr. Stahl moved from Stanford to UC-San Diego in 1988 after federal investigators found him guilty of plagiarism and of writing two “seriously misleading” papers, and required that for five years that he not serve on any U.S. Public Health Service panels and that any institution employing him monitor his grant applications and research.

Russell K. Portenoy, a professor of neurology and professor of family and social medicine at Albert Einstein College of Medicine, is named in an opioids-related lawsuit against drug companies filed by the state of Ohio. He, too, sits outside his college’s ethics policies. That’s because Dr. Portenoy worked primarily as an employee of Beth Israel Hospital, a former teaching affiliate of Einstein, and only was given an Einstein faculty appointment “as a supervisory physician for the rare Einstein medical student who chose to do a palliative medicine elective clerkship at Beth Israel,” Einstein said in a statement.

ADVERTISEMENT

Dr. Portenoy and other academics were described in the Ohio lawsuit as composing a group of “seemingly independent third parties” used by the drug companies “to spread false and deceptive statements about the risks and benefits of opioids.”

Doctors doing the actual prescribing of pain medications, however, are facing much more direct legal peril. They include an Oklahoma doctor, Regan Nichols, who was charged last month by her state’s attorney general with second-degree murder in the overdose deaths of at least five patients.

Universities do not appear to face such direct threats now, said Heather Pierce, senior director for science policy and regulatory counsel at the Association of American Medical Colleges. But, she added, “that’s a risk assessment that they’re doing all the time.”

Paul Basken covers university research and its intersection with government policy. He can be found on Twitter @pbasken, or reached by email at paul.basken@chronicle.com.

We welcome your thoughts and questions about this article. Please email the editors or submit a letter for publication.
Tags
Scholarship & Research
Share
  • Twitter
  • LinkedIn
  • Facebook
  • Email
Paul Basken Bio
About the Author
Paul Basken
Paul Basken was a government policy and science reporter with The Chronicle of Higher Education, where he won an annual National Press Club award for exclusives.
ADVERTISEMENT
ADVERTISEMENT

Related Content

Science Ethics Rules Leave Room for Scandals
The Secret Lives of Big Pharma’s ‘Thought Leaders’

More News

Vector illustration of large open scissors  with several workers in seats dangling by white lines
Iced Out
Duke Administrators Accused of Bypassing Shared-Governance Process in Offering Buyouts
Illustration showing money being funnelled into the top of a microscope.
'A New Era'
Higher-Ed Associations Pitch an Alternative to Trump’s Cap on Research Funding
Illustration showing classical columns of various heights, each turning into a stack of coins
Endowment funds
The Nation’s Wealthiest Small Colleges Just Won a Big Tax Exemption
WASHINGTON, DISTICT OF COLUMBIA, UNITED STATES - 2025/04/14: A Pro-Palestinian demonstrator holding a sign with Release Mahmud Khalil written on it, stands in front of the ICE building while joining in a protest. Pro-Palestinian demonstrators rally in front of the ICE building, demanding freedom for Mahmoud Khalil and all those targeted for speaking out against genocide in Palestine. Protesters demand an end to U.S. complicity and solidarity with the resistance in Gaza. (Photo by Probal Rashid/LightRocket via Getty Images)
Campus Activism
An Anonymous Group’s List of Purported Critics of Israel Helped Steer a U.S. Crackdown on Student Activists

From The Review

John T. Scopes as he stood before the judges stand and was sentenced, July 2025.
The Review | Essay
100 Years Ago, the Scopes Monkey Trial Discovered Academic Freedom
By John K. Wilson
Vector illustration of a suited man with a pair of scissors for a tie and an American flag button on his lapel.
The Review | Opinion
A Damaging Endowment Tax Crosses the Finish Line
By Phillip Levine
University of Virginia President Jim Ryan keeps his emotions in check during a news conference, Monday, Nov. 14, 2022 in Charlottesville. Va. Authorities say three people have been killed and two others were wounded in a shooting at the University of Virginia and a student is in custody. (AP Photo/Steve Helber)
The Review | Opinion
Jim Ryan’s Resignation Is a Warning
By Robert Zaretsky

Upcoming Events

07-31-Turbulent-Workday_assets v2_Plain.png
Keeping Your Institution Moving Forward in Turbulent Times
Ascendium_Housing_Plain.png
What It Really Takes to Serve Students’ Basic Needs: Housing
Lead With Insight
  • Explore Content
    • Latest News
    • Newsletters
    • Letters
    • Free Reports and Guides
    • Professional Development
    • Events
    • Chronicle Store
    • Chronicle Intelligence
    • Jobs in Higher Education
    • Post a Job
  • Know The Chronicle
    • About Us
    • Vision, Mission, Values
    • DEI at The Chronicle
    • Write for Us
    • Work at The Chronicle
    • Our Reporting Process
    • Advertise With Us
    • Brand Studio
    • Accessibility Statement
  • Account and Access
    • Manage Your Account
    • Manage Newsletters
    • Individual Subscriptions
    • Group and Institutional Access
    • Subscription & Account FAQ
  • Get Support
    • Contact Us
    • Reprints & Permissions
    • User Agreement
    • Terms and Conditions
    • Privacy Policy
    • California Privacy Policy
    • Do Not Sell My Personal Information
1255 23rd Street, N.W. Washington, D.C. 20037
© 2025 The Chronicle of Higher Education
The Chronicle of Higher Education is academe’s most trusted resource for independent journalism, career development, and forward-looking intelligence. Our readers lead, teach, learn, and innovate with insights from The Chronicle.
Follow Us
  • twitter
  • instagram
  • youtube
  • facebook
  • linkedin